NPM1 and acute myeloid leukemia: Notably, mutations in NPM1 can be detected in AML at relapse, even many years after the initial diagnosis, so that these mutations recently updated World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia and has been defined as a distinct molecular leukemia in addition it is a reliable biomarker for assessment of disease status in AML.3